What are peptides?

Peptides are the major signalling molecules in the human body. They bind to receptors on the cell surface and tell other cells and molecules what to do. Peptides are an integral part of most biologic processes and are present throughout every cell and tissue in the body.

Peptides and proteins are very similar and like proteins, peptides are naturally present in foods. Peptides are smaller versions of proteins – both proteins and peptides are made up of amino acids, but peptides contain fewer amino acids than proteins.

Because they are smaller, peptides are easier for the body to absorb than proteins. They have been proven to more easily penetrate the skin and intestines, allowing them to enter the bloodstream quicker and more efficiently.

Why has Nuritas chosen to focus on peptides for drug discovery?

As peptides are the major signalling molecules in the human body (most bodily functions communicate via peptides) they offer both significant therapeutic potential and the highest probability of clinical success compared to other methods. There are approximately 60 approved peptide drugs Worldwide, but we believe that the landscape of opportunity in this area is much bigger and largely unexplored. From a bioactivity standpoint, peptides offer a “goldilocks” solution that neither small molecules nor large biologics can offer.

How is your AI platform different from other drug discovery AI platforms?

Not only has Nuritas created the largest database of natural peptides in the world, we have also spent the last five years generating large amounts of assay data on peptide performance, as well as human clinical data from the development and commercialization of consumer peptide products.

This enormous volume of proprietary data that we have generated internally, coupled with curated information from public databases, gives the Nuritas Peptide Finder AI platform a distinct advantage over other artificial intelligence drug discovery initiatives.

Is Nuritas developing its own therapeutic products, or will the pharma pipeline be commercialized via partnerships?

Nuritas is looking at both pathways for future success. We are currently focused on launching our own products in the consumer category (link to ElioLife). In parallel, we are focused on establishing key pharma partnerships to support development of our preclinical therapeutics pipeline and offering access to our AI platform for de novo platform discovery capabilities. Ultimately, we envision being able to identify emerging opportunities from our rich pharma discovery pipeline that may represent opportunities for Nuritas commercialization.

What areas is Nuritas focusing on?

Nuritas is one of the few companies worldwide dedicated to the development of preventative measures, which are key to stemming the tide of chronic disease. By focusing on some of the most significant problems affecting human health, we are providing meaningful solutions to alleviate chronic disease epidemics such as developing natural medicine solutions for diabetes, inflammation, metabolism and helping the aging population crisis that is gripping Europe and the world.

Is Nuritas working on Covid 19?

In conjunction with PRACE (Partnership for Advanced Computing in Europe), we are using our proprietary AI platform to look for peptides that can be used in the treatment of COVID19.